Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors

American Journal of Cardiology

Volumn 110, Issue 3, 2012, Pages 383-391

  Makani, Harikrishna ^a   Messerli, Franz H ^a   Romero, Jorge ^a   Wever Pinzon, Omar ^b   Korniyenko, Aleksander ^a   Berrios, Ronaldo Sevilla ^a   Bangalore, Sripal ^c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; OMAPATRILAT; PERINDOPRIL; QUINAPRIL; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; TRANDOLAPRIL; VERAPAMIL;

ANGIONEUROTIC EDEMA; ARTICLE; EMBASE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ANGIOEDEMA; ANGIOTENSINS; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84863986170     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.03.034     Document Type: Article

References (61)

1. W. Osler Landmark publication from the American Journal of the Medical Sciences: Hereditary angio-neurotic oedema, 1888 Am J Med Sci 339 2010 175 178
2. F.H. Messerli, J. Nussberger Vasopeptidase inhibition and angio-oedema Lancet 356 2000 608 609
3. M.A. Weber, F.H. Messerli Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk Hypertension 51 2008 1465 1467
4. Z.H. Israili, W.D. Hall Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy A review of the literature and pathophysiology Ann Intern Med 117 1992 234 242
5. E.E. Slater, D.D. Merrill, H.A. Guess, P.J. Roylance, W.D. Cooper, W.H. Inman, P.W. Ewan Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition JAMA 260 1988 967 970
6. A. Agostoni, M. Cicardi, M. Cugno, L.C. Zingale, D. Gioffre, J. Nussberger Angioedema due to angiotensin-converting enzyme inhibitors J Immunopharmacol 44 1999 21 25
7. J. Higgins, S. Green Assessing Risk of Bias in Included Studies Cochrane Handbook for Systematic Reviews of Interventions, Version 500 2008 Cochrane Collaboration Oxford
8. D. Moher, D.J. Cook, S. Eastwood, I. Olkin, D. Rennie, D.F. Stroup [Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement] Rev Esp Salud Publica 74 2000 107 118
9. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement BMJ 339 suppl 2009 b2535
10. M.J. Bradburn, J.J. Deeks, J.A. Berlin, A. Russell Localio Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events Stat Med 26 2007 53 77
11. M. Egger, G. Davey Smith, M. Schneider, C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
12. D.G. Altman, J.M. Bland Interaction revisited: the difference between two estimates BMJ 326 2003 219
13. J.T. Wright Jr, G. Bakris, T. Greene, L.Y. Agodoa, L.J. Appel, J. Charleston, D. Cheek, J.G. Douglas-Baltimore, J. Gassman, R. Glassock, L. Hebert, K. Jamerson, J. Lewis, R.A. Phillips, R.D. Toto, J.P. Middleton, S.G. Rostand African American Study of Kidney Disease and Hypertension Study Group Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 2002 2421 2431
14. K. Jamerson, M.A. Weber, G.L. Bakris, B. Dahlöf, B. Pitt, V. Shi, A. Hester, J. Gupte, M. Gatlin, E.J. Velazquez ACCOMPLISH Trial Investigators Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
16. P. Ruggenenti, A. Fassi, A.P. Ilieva, S. Bruno, I.P. Iliev, V. Brusegan, N. Rubis, G. Gherardi, F. Arnoldi, M. Ganeva, B. Ene-Iordache, F. Gaspari, A. Perna, A. Bossi, R. Trevisan, A.R. Dodesini, G. Remuzzi Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators Preventing microalbuminuria in type 2 diabetes N Engl J Med 351 2004 1941 1951
17. M. Cesari, S.B. Kritchevsky, H.H. Atkinson, B.W. Penninx, M. Di Bari, R.P. Tracy, M. Pahor Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study Am Heart J 157 2009 e331 e338
18. J.J. McMurray, J. Ostergren, K. Swedberg, C.B. Granger, P. Held, E.L. Michelson, B. Olofsson, S. Yusuf, M.A. Pfeffer CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771
19. J.G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, J. Taylor PEP-CHF Investigators The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study Eur Heart J 27 2006 2338 2345
20. M. Marre, M. Lievre, G. Chatellier, J.F. Mann, P. Passa, J. Ménard DIABHYCAR Study Investigators Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) BMJ 328 2004 495
21. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
22. W.F. Keane, A. Polis, D. Wolf, E. Faison, S. Shahinfar The long-term tolerability of enalapril in hypertensive patients with renal impairment Nephrol Dial Transplant 12 suppl 2 1997 75 81
23. D. Maclean, L.E. Ramsay, P.J. Richardson Enalapril and nifedipine in the treatment of mild to moderate essential hypertension: a 6 month comparison Br J Clin Pharmacol 30 1990 203 211
24. J.B. Kostis, H.J. Kim, J. Rusnak, T. Casale, A. Kaplan, J. Corren, E. Levy Incidence and characteristics of angioedema associated with enalapril Arch Intern Med 165 2005 1637 1642
25. M. Packer, R.M. Califf, M.A. Konstam, H. Krum, J.J. McMurray, J.L. Rouleau, K. Swedberg Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
26. E. Braunwald, M.J. Domanski, S.E. Fowler, N.L. Geller, B.J. Gersh, J. Hsia, M.A. Pfeffer, M.M. Rice, Y.D. Rosenberg, J.L. Rouleau PEACE Trial Investigators Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med 351 2004 2058 2068
27. C.J. Pepine, J.L. Rouleau, K. Annis, A. Ducharme, P. Ma, J. Lenis, R. Davies, U. Thadani, B. Chaitman, H.E. Haber, S.B. Freedman, M.L. Pressler, B. Pitt QUASAR Study Group Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial J Am Coll Cardiol 42 2003 2049 2059
28. A. Zanchetti, G. Crepaldi, M.G. Bond, G. Gallus, F. Veglia, G. Mancia, A. Ventura, G. Baggio, L. Sampieri, P. Rubba, G. Sperti, A. Magni PHYLLIS Investigators Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS - a randomized double-blind trial Stroke 35 2004 2807 2812
29. R. Ferrari Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study Arch Intern Med 166 2006 659 666
30. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
31. J.B. Kostis, B. Shelton, G. Gosselin, C. Goulet, W.B. Hood Jr, R.M. Kohn, S.H. Kubo, E. Schron, M.B. Weiss, P.W. Willis III, J.B. Young, J. Probstfield Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD) SOLVD Investigators Am Heart J 131 1996 350 355
32. L.H. Lindholm, M. Persson, P. Alaupovic, B. Carlberg, A. Svensson, O. Samuelsson Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study) J Hypertens 21 2003 1563 1574
33. C.B. Granger, J.J. McMurray, S. Yusuf, P. Held, E.L. Michelson, B. Olofsson, J. Ostergren, M.A. Pfeffer, K. Swedberg CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
34. N. Chaturvedi, M. Porta, R. Klein, T. Orchard, J. Fuller, H.H. Parving, R. Bilous, A.K. Sjolie DIRECT Programme Study Group Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials Lancet 372 2008 1394 1402
35. M.A. Konstam, J.D. Neaton, K. Dickstein, H. Drexler, M. Komajda, F.A. Martinez, G.A. Riegger, W. Malbecq, R.D. Smith, S. Guptha, P.A. Poole-Wilson HEAAL Investigators Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial Lancet 374 2009 1840 1848
36. E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, E. Ritz, R.C. Atkins, R. Rohde, I. Raz Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
37. B. Dahlöf, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
38. J.B. McGill, P.A. Reilly Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial Clin Ther 23 2001 833 850
39. J.P. Baguet, R. Asmar, P. Valensi, S. Nisse-Durgeat, J.M. Mallion Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study Vasc Health Risk Manag 5 2009 175 183
40. H. Haller, S. Ito, J.L. Izzo Jr, A. Januszewicz, S. Katayama, J. Menne, A. Mimran, T.J. Rabelink, E. Ritz, L.M. Ruilope, L.C. Rump, G. Viberti ROADMAP Trial Investigators Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes N Engl J Med 364 2011 907 917
41. S. Yusuf, K. Teo, C. Anderson, J. Pogue, L. Dyal, I. Copland, H. Schumacher, G. Dagenais, P. Sleight Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 2008 1174 1183
42. S. Julius, S.D. Nesbitt, B.M. Egan, M.A. Weber, E.L. Michelson, N. Kaciroti, H.R. Black, R.H. Grimm Jr, F.H. Messerli, S. Oparil, M.A. Schork Trial of Preventing Hypertension (TROPHY) Study Investigators Feasibility of treating prehypertension with an angiotensin-receptor blocker N Engl J Med 354 2006 1685 1697
43. M. Volpe, Z. Junren, T. Maxwell, A. Rodriguez, R. Gamboa, P. Gomez-Fernandez, G. Ortega-Gonzalez, N. Matadamas, F. Rodriguez, B. Dass, C. Kyle, L. Clarysse, A. Bryce, E. Moreno-Heredia, G. Germano, L. Gilles, R.D. Smith, J.E. Sanderson CDSP-944 Study Group Comparison of the blood pressure-lowering effects and tolerability of losartan- and amlodipine-based regimens in patients with isolated systolic hypertension Clin Ther 25 2003 1469 1489
44. B. Pitt, R. Segal, F.A. Martinez, G. Meurers, A.J. Cowley, I. Thomas, P.C. Deedwania, D.E. Ney, D.B. Snavely, P.I. Chang Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE) Lancet 349 1997 747 752
45. A. Himmelmann, S. Keinänen-Kiukaanniemi, A. Wester, J. Redón, R. Asmar, T. Hedner Effect Study Group The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension Blood Press 10 2001 43 51
46. B.E. Karlberg, L.E. Lins, K. Hermansson Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension TEES Study Group J Hypertens 17 1999 293 302
47. J.M. Neutel, W.H. Frishman, S. Oparil, V. Papademitriou, G. Guthrie Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension Am J Ther 6 1999 161 166
48. S. Yusuf, K.K. Teo, J. Pogue, L. Dyal, I. Copland, H. Schumacher, G. Dagenais, P. Sleight, C. Anderson Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
49. K. Dickstein, J. Kjekshus OPTIMAAL Steering Committee of the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Lancet 360 2002 752 760
50. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, J.L. Rouleau, L. Kober, A.P. Maggioni, S.D. Solomon, K. Swedberg, F. Van de Werf, H. White, J.D. Leimberger, M. Henis, S. Edwards, S. Zelenkofske, M.A. Sellers, R.M. Califf Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
51. M.J. Brown, G.T. McInnes, C.C. Papst, J. Zhang, T.M. MacDonald Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial Lancet 377 2011 312 320
52. W.B. White, R. Bresalier, A.P. Kaplan, B.F. Palmer, R.H. Riddell, A. Lesogor, W. Chang, D.L. Keefe Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension J Clin Hypertens (Greenwich) 12 2010 765 775
53. J. Nussberger, M. Cugno, M. Cicardi Bradykinin-mediated angioedema N Engl J Med 347 2002 621 622
54. M. Bas, V. Adams, T. Suvorava, T. Niehues, T.K. Hoffmann, G. Kojda Nonallergic angioedema: role of bradykinin Allergy 62 2007 842 856
55. D.J. Campbell, H. Krum, M.D. Esler Losartan increases bradykinin levels in hypertensive humans Circulation 111 2005 315 320
56. L.C. Zingale, L. Beltrami, A. Zanichelli, L. Maggioni, E. Pappalardo, B. Cicardi, M. Cicardi Angioedema without urticaria: a large clinical survey CMAJ 175 2006 1065 1070
57. C.J. Beavers, S.P. Dunn, T.E. Macaulay The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema Ann Pharmacother 45 2011 520 524
58. B.R. Haymore, K.J. DeZee Use of angiotensin receptor blockers after angioedema with an angiotensin-converting enzyme inhibitor Ann Allergy Asthma Immunol 103 2009 83 84
59. N.J. Brown, W.A. Ray, M. Snowden, M.R. Griffin Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema Clin Pharmacol Ther 60 1996 8 13
60. J.V. Gainer, J.H. Nadeau, D. Ryder, N.J. Brown Increased sensitivity to bradykinin among African Americans J Allergy Clin Immunol 98 1996 283 287
61. M. Cugno, P. Agostoni, D. Mari, P.L. Meroni, L. Gregorini, M. Bussotti, G.B. Anguissola, F. Donatelli, J. Nussberger Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment Relationships with endothelial function, coagulation and inflammation Br J Haematol 130 2005 113 120